If a cancer patient has bone metastases, they will frequently have anemia as well. Given that the bone marrow is the site of blood cell formation, this observation is perhaps not unexpected. But its molecular underpinnings had been unclear to date. Now, researchers at Princeton University and the Rutgers Cancer Institute of New Jersey have identified a specialized group of iron-transporting macrophages in the metastasis-anemia link.
Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed glutaminyl-peptide cyclotransferase (QPCT; QC) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of cancer, fibrosis, atherosclerosis and more.
Aligos Therapeutics Inc. has identified programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B (HBV).
Avenzo Therapeutics Inc. has obtained IND clearance by the FDA for AVZO-103 (formerly VAC-103), a nectin-4/TROP2 bispecific antibody-drug conjugate (ADC).
In an effort to exploit the advantages of therapeutic bacteria and viruses while avoiding their disadvantages, researchers at Columbia and Rockefeller Universities have developed an anticancer platform called CAPPSID (Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery).
Scientists at National University of Singapore and Agency for Science Technology & Research Bioprocessing Technology Institute have identified MAPK-interacting kinase (MNK) inhibitors, particularly MNK1 and MNK2 inhibitors reported to be useful for the treatment of triple-negative breast cancer (TNBC) metastatic to the brain.
RSS
